Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony Lemarié has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • When extended metabolites profiling helps the prediction of local relapse in glioblastoma: a retrospective study using MRI and MRSI

    by Wafae Labriji, Amel Aissaoui, Jean-Yves Tourneret, Lotfi Chaari, Lucie Piram, Umberto Sabatini, Anthony Lemarié, Elizabeth Moyal Cohen-Jonathan, Soléakhéna Ken

    Objectives: This study investigates whether integrating postoperative MRI with advanced MR spectroscopic imaging (MRSI) improves voxel-wise prediction of future local recurrence in glioblastoma (GBM). Methods: Fifty-eight GBM patients included in the clinical trial Spectro-Glio were retrospectively analyzed with post-operative baseline for MRI and MRSI processed to generate voxel-level features. MRSI metabolites were quantified using a Bayesian sparse model, enabling reliable estimation of both conventional and extended metabolite panels. Ground-truth relapse labels were derived from longitudinal follow-up MRI to track voxel-wise tissue class changes over time. Voxel-wise relapse prediction was performed using 3 supervised classifiers (Elastic Net, Random Forest, RBF-SVM) evaluated with leave-one-patient-out cross-validation. Feature sets combining MRI intensities, spatial descriptors, and MRSI metabolites were systematically compared. Results: MRI-only models showed moderate discrimination (AUC, ≤0.70). Using MRSI features alone significantly improved prediction performance, with further improvements when extending the metabolite basis beyond conventional markers (AUC, 0.77-0.82; P < .001). Spatial descriptors and MRSI-based models provided the largest performance gains (AUC up to 0.95). SHAP analysis consistently identified both conventional and secondary metabolites among the most influential predictors, particularly in the absence of spatial features. Conclusions: Postoperative MRSI and spatial descriptors significantly enhances voxel-wise prediction of GBM relapse, particularly when using an extended metabolite basis beyond conventional markers. Advances in knowledge: This study supports the clinical potential of MRSI alongside spatial features to identify relapse sites not captured by anatomical MRI alone. MRSI integration of extended metabolites provides insights for voxel-wise relapse prediction, supporting complementary characterization of tissue at risk.

  • Open Access

    Fluopyram induces behavioural, hepatotoxic and metabolic alterations in fish at environmentally relevant concentrations

    by Lucie Bouly, Lisa Jacquin, Séverine Paris-Palacios, Camille Pasquet, Jean-Marc Bonmatin, Océane Delos, Lara Galès, Justine Bertrand-Michel, Floriant Bellvert, Marion Vivant, et al.

  • Report of the scientific network Holimitox on succinate dehydrogenase inhibitor (SDHI) pesticides: new insights and challenges with an EcoHealth approach—presentations and round tables from the Holimitox day on November 7, 2024

    by Jean-Marc Bonmatin, François Chamaraux, Séverine Jean, Emmanuella Abbey, Erwan Bézard, Lucie Bouly, Bénédicte Buffin-Meyer, Marie Buleon, Thomas Castellino, Frédéric Delbac, et al.

    Succinate dehydrogenase (complex II of the mitochondrial respiratory chain) plays an essential role in cellular respiration in all living organisms. Its inhibition in humans leads to severe pathologies. It is targeted by succinate dehydrogenase inhibitor (SDHI) pesticides that are seeing a global rise in usage within the farming industry. Concerned about the systemic toxic effects, the use and the regulation of SDHI pesticides, the interdisciplinary Holimitox consortium, made up of sixteen French research laboratories, has been working on the subject for four years. This article is a report of the concluding meeting of the consortium, combining research programme synthesis phases and round table discussions. The Holimitox consortium emphasizes the importance of taking an interest in this family of pesticides, which are still little known yet rapidly expanding, using an integrative EcoHealth approach. This is because the challenges of public health, environmental protection, and biodiversity require a detailed understanding of food and agricultural production chains, economic issues, and the regulatory assessment procedures for these pesticides.


  • Open Access

    Early metabolic reprogramming and carbonic anhydrase IX-mediated extracellular acidification drive radiotherapy-induced glioblastoma cell dedifferentiation

    by Perrine Dahan, Tom Maillet, Laure Malric, Caroline Delmas, Vincent Lubrano, Judith Martinez-Gala, Guillaume Flandin, Amélie Aboudaram, Cécile Héliès-Toussaint, Nicolas Skuli, et al.

    Background: Glioblastomas (GBM) are brain tumors with the worst prognosis despite treatment with surgery and radio/chemotherapy, emphasizing the need for new therapies and improved treatment efficacy. Previously, we showed that clinically relevant ionizing radiation (IR) doses enhance GBM cell dedifferentiation into a stem-like phenotype, increasing stemness markers, self-renewal, and tumorigenic abilities. This work focuses on identifying early mechanisms driving this plasticity, particularly metabolic adaptations, as tumor metabolism may support therapy resistance and recurrence. Methods: In this study, primary cell lines were established from GBM biopsies of several patients and cultured either in restrictive medium to form neurospheres (NS) enriched in GBM stem-like cells (GSC) or in normal medium to obtain their differentiated progenies. These differentiated GBM cells were then subjected to a short-term dedifferentiation protocol after IR (24 to 72 h) to characterize their metabolic and phenotypic properties. Results: We found that early stem marker increases after IR exposure coincide with higher oxygen consumption rate (OCR), mitochondrial ATP production, and extracellular acidification rate (ECAR). However, lactate production remained unchanged, and glucose uptake showed only a transient, nonspecific increase. This shift to oxidative mitochondrial metabolism, coupled with extracellular acidosis, promotes a stem-like phenotype and is associated with Carbonic Anhydrase IX (CA9) overexpression, an extracellular membrane protein producing H + to buffer intracellular pH. CA9 downregulation via ShRNA reduces extracellular acidification and blocks early IR-induced dedifferentiation, such as neurosphere (NS) formation and stem marker overexpression. Similarly, increased OCR and ECAR, often linked to CA9 overexpression, are observed in patient-derived GSC compared to their differentiated progenies. Conclusions: These findings highlight CA9 as a potential target to block IR-induced early dedifferentiation process as well as the specific metabolic state of GSC. Our study strengthens the therapeutic potential of CA9 inhibition to limit GBM-associated acidic extracellular environment and enhance radiotherapy efficiency by limiting tumor cell plasticity.


  • Open Access

    Fluopyram SDHI pesticide alters fish physiology and behaviour despite low in vitro effects on mitochondria

    by Lucie Bouly, Lisa Jacquin, Florian Chapeau, Jean-Marc Bonmatin, Myriam Cousseau, Aurianne Hagimont, Pascal Laffaille, Bénédicte Lalot, Anthony Lemarié, Camille Pasquet, et al.


  • Open Access

    Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells

    by Audrey Frances, Audrey Lumeau, Nicolas Bery, Marion Gayral, Lucille Stuani, Marie Sorbara, Estelle Saland, Delphine Pagan, Naïma Hanoun, Jérôme Torrisani, et al.

    Cytidine deaminase (CDA) converts cytidine and deoxycytidine into uridine and deoxyuridine as part of the pyrimidine salvage pathway. Elevated levels of CDA are found in pancreatic tumors and associated with chemoresistance. Recent evidence suggests that CDA has additional functions in cancer cell biology. In this work, we uncover a novel role of CDA in pancreatic cancer cell metabolism. CDA silencing impairs mitochondrial metabolite production, respiration, and ATP production in pancreatic cancer cells, leading to a so-called Pasteur effect metabolic shift towards glycolysis. Conversely, we find that CDA expression promotes mitochondrial biogenesis and oxidative phosphorylation, independently of CDA deaminase activity. Furthermore, we observe that patient primary cells overexpressing CDA are more sensitive to mitochondria-targeting drugs. Collectively, this work shows that CDA plays a non-canonical role in pancreatic cancer biology by promoting mitochondrial function, which could be translated into novel therapeutic vulnerabilities.


  • Open Access

    The STEMRI trial: Magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma stem-like cells

    by Anthony Lemarié, Vincent Lubrano, Caroline Delmas, Amélie Lusque, Juan-Pablo Cerapio, Marion Perrier, Aurore Siegfried, Florent Arnauduc, Yvan Nicaise, Perrine Dahan, et al.

    Despite maximally safe resection of the magnetic resonance imaging (MRI)–defined contrast-enhanced (CE) central tumor area and chemoradiotherapy, most patients with glioblastoma (GBM) relapse within a year in peritumoral FLAIR regions. Magnetic resonance spectroscopy imaging (MRSI) can discriminate metabolic tumor areas with higher recurrence potential as CNI+ regions (choline/ N -acetyl-aspartate index >2) can predict relapse sites. As relapses are mainly imputed to glioblastoma stem-like cells (GSCs), CNI+ areas might be GSC enriched. In this prospective trial, 16 patients with GBM underwent MRSI/MRI before surgery/chemoradiotherapy to investigate GSC content in CNI−/+ biopsies from CE/FLAIR. Biopsy and derived-GSC characterization revealed a FLAIR/CNI+ sample enrichment in GSC and in gene signatures related to stemness, DNA repair, adhesion/migration, and mitochondrial bioenergetics. FLAIR/CNI+ samples generate GSC-enriched neurospheres faster than FLAIR/CNI−. Parameters assessing biopsy GSC content and time-to-neurosphere formation in FLAIR/CNI+ were associated with worse patient outcome. Preoperative MRI/MRSI would certainly allow better resection and targeting of FLAIR/CNI+ areas, as their GSC enrichment can predict worse outcomes.


  • Open Access

    Data from Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells

    by Laure Malric, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, Sabrina Boyrie, Pauline Deshors, Vincent Lubrano, Dina Ferreira Da Mota, Julia Gilhodes, et al.

    Glioblastomas (GB) are malignant brain tumors with poor prognosis despite treatment with surgery and radio/chemotherapy. These tumors are defined by an important cellular heterogeneity and notably contain a subpopulation of GB-initiating cells (GIC), which contribute to tumor aggressiveness, resistance, and recurrence. Some integrins are specifically expressed by GICs and could be actionable targets to improve GB treatment. Here, integrin β8 (ITGB8) was identified as a potential selective target in this highly tumorigenic GIC subpopulation. Using several patient-derived primocultures, it was demonstrated that ITGB8 is overexpressed in GICs compared with their differentiated progeny. Furthermore, ITGB8 is also overexpressed in GB, and its overexpression is correlated with poor prognosis and with the expression of several other classic stem cell markers. Moreover, inhibiting ITGB8 diminished several main GIC characteristics and features, including self-renewal ability, stemness, migration potential, and tumor formation capacity. Blockade of ITGB8 significantly impaired GIC cell viability via apoptosis induction. Finally, the combination of radiotherapy and ITGB8 targeting radiosensitized GICs through postmitotic cell death.Implications:This study identifies ITGB8 as a new selective marker for GICs and as a promising therapeutic target in combination with chemo/radiotherapy for the treatment of highly aggressive brain tumors.

  • Open Access

    Supplementary Figures 1-5 from Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells

    by Laure Malric, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, Sabrina Boyrie, Pauline Deshors, Vincent Lubrano, Dina Ferreira Da Mota, Julia Gilhodes, et al.

    S1. Phenotypic characterization of GIC-enriched neurospheres and related GDC cultures. S2. Expression of major integrins in GIC compared to GDC. S3. Correlation of ITGB8 and stem/differentiated markers in GB patients from the TCGA database. S4. Immunohistological pattern of ITGβ8 and Sox2 staining. S5. siRNA-mediated ITGβ8 knock-down impairs GIC stemness and induces apoptosis.

  • Open Access

    Data from Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells

    by Laure Malric, Sylvie Monferran, Caroline Delmas, Florent Arnauduc, Perrine Dahan, Sabrina Boyrie, Pauline Deshors, Vincent Lubrano, Dina Ferreira Da Mota, Julia Gilhodes, et al.

    Glioblastomas (GB) are malignant brain tumors with poor prognosis despite treatment with surgery and radio/chemotherapy. These tumors are defined by an important cellular heterogeneity and notably contain a subpopulation of GB-initiating cells (GIC), which contribute to tumor aggressiveness, resistance, and recurrence. Some integrins are specifically expressed by GICs and could be actionable targets to improve GB treatment. Here, integrin β8 (ITGB8) was identified as a potential selective target in this highly tumorigenic GIC subpopulation. Using several patient-derived primocultures, it was demonstrated that ITGB8 is overexpressed in GICs compared with their differentiated progeny. Furthermore, ITGB8 is also overexpressed in GB, and its overexpression is correlated with poor prognosis and with the expression of several other classic stem cell markers. Moreover, inhibiting ITGB8 diminished several main GIC characteristics and features, including self-renewal ability, stemness, migration potential, and tumor formation capacity. Blockade of ITGB8 significantly impaired GIC cell viability via apoptosis induction. Finally, the combination of radiotherapy and ITGB8 targeting radiosensitized GICs through postmitotic cell death.Implications:This study identifies ITGB8 as a new selective marker for GICs and as a promising therapeutic target in combination with chemo/radiotherapy for the treatment of highly aggressive brain tumors.